Stepping Into the Era of Combination Cancer Therapies, Part 2: Combining Targeted Therapies

"Philadelphia, PA - The AACR 2015 Annual Meeting - Ursala Matulonis discusses her research during the AACR Press Conference at the American Association for Cancer Research Annual Meeting here today, Tuesday April 21, 2015. More than 18,000 physicians, researchers, health care professionals, cancer survivors and patient advocates are expected to attend the meeting at the Pennsylvania Convention Center. The Annual Meeting highlights the latest findings in all major areas of cancer research from basic through clinical and epidemiological studies. Photo by © AACR/Todd Buchanan 2015 Contact Info: Keywords: 15AACR_Meet the Editors: Cancer Discovery session"

In my first post in this series highlighting some of the studies presented at the AACR Annual Meeting 2015 that hold promise for combination cancer therapies, I discussed clinical trials …

Read More

Behind the Scenes: Recognizing and Supporting Progress in Cancer Research at the AACR Annual Meeting

Awards 300x300

In addition to providing a forum for attendees to learn, network, and share information and ideas, the Annual Meeting presents a valuable opportunity for the AACR to recognize our research grant recipients, who range from promising early-career investigators to established researchers, and to honor researchers who have made significant contributions to the cancer research enterprise.

Read More

Dutch-American Research Team Aiming to Improve Colorectal Cancer Screening


Despite current screening efforts, colorectal cancer is the fourth most commonly diagnosed cancer worldwide and the fifth leading cause of cancer-related death. A newly formed trans-Atlantic team of researchers brought together by Stand Up To Cancer (SU2C) and the Dutch Cancer Society, KWF Kankerbestrijding (KWF), is hoping to change this by developing a new molecular test for stool-based colorectal cancer screening.

Read More

New Findings Open Doors for Rational Lung Cancer Treatment Strategies

ALK with crizotinib

In a study published Tuesday in the American Association for Cancer Research’s journal Clinical Cancer Research, researchers identified two novel mutations that cause resistance to alectinib, a drug that belongs …

Read More